NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

Standard BioTools Inc. (LAB) Stock Analysis

Standard BioTools Inc. (LAB) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

LAB

$0.69

+$0.02 (+2.99%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LAB with… →

LAB Key Statistics

As of Sep 4, 2026
Trading
Open
$0.68
Previous Close
$0.67
Day's Range
0.66–0.69
52-Week Range
0.63–1.72
Volume
1.76M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.37
Valuation
Market Cap
$269.11M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.18
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.13
Financials (FY)
Revenue (FY)
$85.33M−6.24%
Net Income (FY)
−$74.90M
Profit marginThe share of revenue left as profit after all costs and taxes.
100.36%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
392.58M
1-Year Return
−46.51%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
3.23M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

LAB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−46.09%
2025−26.86%
2024−20.81%
2023+88.89%
2022−70.15%
2021−34.67%
2020+72.41%
2019−59.63%
2018+46.35%
2017−19.09%
2016 (partial year)−18.75%

As of September 4, 2026.

LAB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$85.33M−$74.90M−87.8%
2024$91.01M−$138.89M−152.6%
2023$106.34M−$74.66M−70.2%
2022$97.95M−$190.10M−194.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$85.33M$42.54M−$93.31M−$74.90M−87.8%
2024$91.01M$44.88M−$87.01M−$138.89M−152.6%
2023$106.34M$50.45M−$63.04M−$74.66M−70.2%
2022$97.95M$37.05M−$102.62M−$190.10M−194.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LAB Valuation vs Medical Devices Median

Median of 151 stocks
MetricLABMedical Devices medianvs median
P/S ratio3.182.987% above
Profit margin100.36%−1.69%102.1 pts above

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Standard BioTools Inc. (LAB) is capitalised at $269.11M on the latest close. It is classified in the Medical Devices industry, within the Healthcare sector. The company reports 385 employees.

The 52-week range on file runs from $0.63 to $1.72. The most recent close on file for LAB is $0.69, dated September 4, 2026. That is +$0.02 (+2.99%) against the previous close. The latest close sits 9.52% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $85.33M. Against the prior fiscal year total of $91.01M, that is a change of −6.24%. The same year closed with a net loss of $74.90M. Profit margin runs at 100.37%. That is 102.1 percentage points above the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −0.13.

Across the 4 fiscal years on file, revenue moves from $97.95M in 2022 to $85.33M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 3.18 times revenue. On price-to-sales that is 6.89% above the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

Beta against the wider market is reported at 1.37. Annualized volatility over the trailing 10 years is 83.74%. Over the trailing twelve months the price has returned −46.51%. Measured over 10 years, that is −22.48% a year compounded.

Growth & Income

No dividend is on file for LAB.

Across the complete calendar years on file, 2023 returned +88.89% and 2022 returned −70.15%. Of the 9 complete calendar years on file, 3 finished higher. So far in 2026 the price is −46.09%.

Peer Comparison

Standard BioTools Inc. (LAB) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Standard BioTools Inc. LAB $269.11M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Standard BioTools Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Standard BioTools Inc.

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.

Visit website →